Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Eric Liebler, Founder and Former President of Nautilus Neurosciences, Joins ElectroCore



 Eric Liebler, Founder and Former President of Nautilus Neurosciences, Joins
                                 ElectroCore

PR Newswire

MORRIS PLAINS, N.J., Jan. 9, 2013

MORRIS PLAINS, N.J., Jan. 9, 2013 /PRNewswire/ -- ElectroCore®, a company
dedicated to developing effective, non-invasive Vagal Nerve Stimulation (nVNS)
therapies for serious neurological conditions and bronchoconstriction,
announced today that Eric Liebler, co-founder and former President of Nautilus
Neurosciences, Inc., has joined ElectroCore as VP, Scientific, Medical and
Governmental Affairs.

Mr. Liebler brings more than 20 years of neurological industry and association
experience to ElectroCore. In 2009, he co-founded Nautilus Neurosciences, a
neurology-focused specialty pharmaceutical company focused on identifying and
developing drugs benefitting those affected by neurological disorders, to
market Cambia® for the treatment of acute migraine.  At Nautilus, Mr. Liebler
was involved in all facets of the company's organization and early success
including initial funding, product commercialization and sales and marketing.

"Eric's deep expertise across many facets of neurology will be a valuable
asset to ElectroCore as we continue to grow in the field of non-invasive vagal
stimulation," said JP Errico, CEO of ElectroCore. "His industry experience and
ability to thrive in an entrepreneurial setting will benefit ElectroCore as we
explore nVNS across several serious neurological conditions."

Mr. Liebler has held leadership positions at Elan, Amarin, Enzon
Pharmaceuticals, Questcor Pharmaceuticals, and Pharmacopeia. He founded Nisola
LLC, an advocacy and business strategy-consulting firm focused on serving
clients in the field of neurology, and sat on the Board of Trustees of the
American Academy of Neurology Foundation (now the American Brain Foundation)
for more than a decade. Mr. Liebler began his career at Athena Neurosciences,
a pioneer in the development of neurology drugs.

"ElectroCore's nVNS devices have the potential to be game-changers in a broad
range of serious conditions," said Liebler. "I'm thrilled to join a team
that's committed to bringing meaningful treatment advances to patients
suffering from migraines, cluster headaches and epilepsy."

About ElectroCore®
ElectroCore is a healthcare company focused on non-invasive neuromodulation
therapies for the treatment of diseases and disorders. The company has
developed non-invasive Vagal Nerve Simulation (nVNS) therapies intended to
treat and/or prevent symptoms of a number of highly prevalent and disabling
conditions. ElectroCore currently has three commercial products on the market:
GammaCore®, AlphaCore®, and GammaCore VET™. The company is headquartered in
Morris Plains, NJ, with international offices in Stockholm, Sweden, Hamilton,
Bermuda, and Sydney, Australia.

For more information, visit: http://www.electrocoremedical.com/.

SOURCE ElectroCore Medical

Website: http://www.electrocoremedical.com
Contact: Corporate, Jennifer Berman, ElectroCore Medical, +1-617-620-8570,
jennifer.berman@electrocoremedical.com; or Media,Tony Plohoros, 6 Degrees
Communications, +1-908-591-2839, tplohoros@6degreespr.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement